The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EORTC CLTF 2021 | PROCLIPI: identification of key prognostic factors in CTCL
Julia Jane Scarisbrick, MBChB, FRCP, MD, University Hospital Birmingham, Birmingham, UK, discusses the findings of the Prospective Cutaneous Lymphoma International Prognostic Indices (PROCLIPI) study, investigating prognostic factors in patients with cutaneous T-cell lymphoma (CTCL). Prof. Scarisbrick reports that data form over 200 patients, of which around 70% had early-stage disease, has been analyzed in the study. In the early-stage setting, the presence of plaques, older age, folliculotropic disease and raised serum LDH has been found to be associated with worse outcomes. In the late-stage setting, lymph node involvement was found to be the most significant prognostic factor. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.
